Emla Cream 5%

Package leaflet: Information for the user

EMLA 5% w/w Cream

lidocaine/prilocaine

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

What is in this leaflet

1. What EMLA Cream is and what it is used for
2. What you need to know before you use EMLA Cream
3. How to use EMLA Cream
4. Possible side effects
5. How to store EMLA Cream
6. Contents of the pack and other information

1. What EMLA Cream is and what it is used for

EMLA Cream contains two active substances called lidocaine and prilocaine. These belong to a group of medicines called local anaesthetics.

EMLA Cream works by numbing the surface of the skin for a short time. It is put on the skin before certain medical procedures. This helps to stop pain on the skin; however you may still have the feelings of pressure and touch.

Adults, Adolescents and Children

It can be used to numb the skin before:

Adults and Adolescents

It can also be used:

A doctor or nurse should supervise the use of EMLA Cream on the genitals.

Adults

It can also be used to numb the skin before:

2. What you need to know before you use EMLA Cream

Do not use EMLA Cream:

Warnings and precautions

Talk to your doctor or pharmacist before using EMLA Cream:

Due to the potentially enhanced absorption on the newly shaven skin, it is important to follow the recommended dosage, skin area and application time.

Avoid getting EMLA Cream in the eyes, as it may cause irritation. If you accidentally get EMLA Cream in your eye, you should immediately rinse it well with lukewarm water or salt (sodium chloride) solution. Be careful to avoid getting anything in your eye until feeling returns.

EMLA Cream should not be applied to an impaired eardrum.

When you use EMLA Cream before being vaccinated with live vaccines (e.g. tuberculosis vaccine), you should return to your doctor or nurse after the time period requested to follow-up the vaccination result.

Children and adolescents

In infants/newborn infants younger than 3 months a transient, clinically not relevant increase in blood pigment levels “methaemoglobinaemia” is commonly observed up to 12 hours after EMLA Cream is put on.

The effectiveness of EMLA Cream when drawing blood from the heel of newborn infants or to provide adequate analgesia for circumcision could not be confirmed in clinical studies.

EMLA Cream should not be applied to the genital mucosa (e.g. in the vagina) of children (below 12 years of age) owing to insufficient data on absorption of active substances.

EMLA Cream should not be used in children younger than 12 months of age who are being treated at the same time with other medicines that affect blood pigment levels “methaemoglobinaemia” (e.g. sulphonamides, see also section 2 Other medicines and EMLA Cream).

EMLA Cream should not be used in preterm newborn infants.

Other medicines and EMLA Cream

Tell your doctor or pharmacist if you are using / taking, have recently used / taken or might use / take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because EMLA Cream can affect the way some medicines work and some medicines can have an effect on EMLA Cream.

In particular, tell your doctor or pharmacist if you or your child have recently used or been given any of the following medicines:

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

Occasional use of EMLA Cream during pregnancy is unlikely to have any adverse effects on the foetus.

The active substances in EMLA Cream (lidocaine and prilocaine) are excreted into breast milk. However, the amount is so small that there is generally no risk to the child.

Animal studies have shown no impairment of male or female fertility.

Driving and using machines

EMLA Cream has no or negligible influence on the ability to drive and use machines when used at the recommended doses.

EMLA Cream contains macrogolglycerol hydroxystearate

Macrogolglycerol hydroxystearate may cause skin reactions.

3. How to use EMLA Cream

Always use EMLA Cream exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Using EMLA Cream

Do not use EMLA Cream on the following areas:

Persons frequently applying or removing cream should ensure that contact is avoided in order to prevent the development of hypersensitivity.

The protective membrane of the tube is perforated by applying the cap.

Use on the skin before small procedures (such as having a needle put in or minor skin operations):

When you apply the cream, it is very important to exactly follow the instructions below:

1. Squeeze the cream into a mound where it is needed on your skin (for example where the needle is going to be put in). A line of cream of about 3.5 cm from the 30 g tube is equal to 1 g of cream. Half a 5 g tube corresponds to about 2 g EMLA Cream. Do not rub the cream in.

2. Peel the paper layer from the ‘centre cut-out’ of the non-adhesive side of the dressing (leaving a frame of paper).

3. Remove the cover of the adhesive side of the dressing.

4. Place the dressing carefully over the mound of cream. Do not spread the cream under the dressing.

5. Remove the paper backing. Smooth down the edges of the dressing carefully. Then leave it in place for at least 60 minutes if the skin has not been damaged. The cream should not be left in place for more than 60 minutes in children under 3 months or for more than 30 minutes in children with an itchy skin condition called ‘atopic dermatitis’. If the cream is used on the genitals or on ulcers, shorter applications times may be used as described below. 

6. Your doctor or nurse will take the dressing off and remove the cream just before they do the medical procedure (for example just before the needle is put in).

Use on larger areas of newly shaven skin before outpatient procedures (such as hair removal techniques):

The usual dose is 1 g of cream for each area of skin that is 10 cm² (10 square centimetres) in size, applied for 1 to 5 hours under a dressing. EMLA Cream should not be used on an area of newly shaven skin larger than 600 cm² (600 square centimetres, e.g. 30 cm by 20 cm) in size. The maximum dose is 60 g.

Use on the skin before hospital procedures (such as split-skin grafting) that require deeper skin anaesthesia:

Use on the skin prior to removal of wart-like spots called “mollusca”

Use on genital skin before injections of local anaesthetics

Use on the genitals before minor skin surgery (such as removal of warts)

Use on leg ulcers before cleaning or removal of damaged skin

If you use more EMLA Cream than you should

If you use more EMLA Cream than your doctor, pharmacist or nurse has told you to, talk to one of them straight away, even if you do not feel any symptoms.

Symptoms of using too much EMLA Cream are listed below. These symptoms are unlikely to happen if EMLA Cream is used as recommended.

In serious cases of overdose, symptoms may include fits, low blood pressure, slowed breathing, stopped breathing and altered heartbeat. These effects may be life-threatening.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor or pharmacist if any of the following side effects bother you or do not seem to go away. Tell your doctor about anything else that makes you feel unwell while you are using EMLA Cream.

A mild reaction (paleness or redness of the skin, slight puffiness, initial burning or itching) may occur on the area on which EMLA is used. These are normal reactions to the cream and the anaesthetics and will disappear in a short while without any measures being needed.

If you experience any troublesome or unusual effects while you are using EMLA, stop using it and check with your doctor or pharmacist as soon as possible.

Common (may affect up to 1 in 10 people)

Uncommon (may affect up to 1 in 100 people)

Rare (may affect up to 1 in 1,000 people)

Additional side effects in children

Methaemoglobinaemia, a blood disorder, which is more frequently observed, often in connection with overdose in newborn infants and infants aged 0 to 12 months.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below).

Ireland

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie

Malta

ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store EMLA Cream

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the package and tube after “EXP”. The expiry date refers to the last day of that month.

Do not freeze.

Keep the tube tightly closed.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What EMLA Cream contains

What EMLA Cream looks like and contents of the pack

White, homogenous cream.

It is packed in an aluminium tube with a polypropylene cap with a piercing device.

EMLA is available in packs of:

1 tube containing 5 g cream

1 tube containing 5 g cream + 2 dressings

1 tube containing 5 g cream + 3 dressings

3 tubes containing 5 g cream + 8 dressings

5 tubes containing 5 g cream

5 tubes containing 5 g cream + 10 dressings

5 tubes containing 5 g cream + 12 dressings

10 tubes containing 5 g cream + 25 dressings

25 tubes containing 5 g cream

25 tubes containing 5 g cream + 50 dressings

1 tube containing 30 g cream

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

The Marketing Authorisation for EMLA 5% w/w Cream marketed in Ireland and Malta is held by

Aspen Pharma Trading Limited
3016 Lake Drive
Citywest Business Campus
Dublin 24
Ireland
IE Tel: +353 (0)1 6308400
MT Tel: +356 21497982

EMLA 5% w/w Cream is manufactured by

AstraZeneca AB
Astraallén
Gärtunaporten, (B674:5)
S-151 85, Södertälje
Sweden

or

Recipharm Karlskoga AB
Björkbornsvägen 5
SE-691 33 Karlskoga
Sweden
 
or 

Aspen Bad Oldesloe GmbH, 32-36 Industriestrasse, 23843 Bad Oldesloe, Germany

This medicinal product is authorised in the Member States of the EEA under the following names:

Austria Emla 5% - Creme

Belgium Emla 25mg/25mg crème

Cyprus Emla Cream 5%

Czech Republic Emla krém 5%

Denmark Emla

Finland EMLA

France EMLA 5 POUR CENT, crème

Germany EMLA

Greece EMLA

Iceland Emla

Ireland EMLA 5% w/w Cream

Italy EMLA

Latvia Emla 5 % krēms

Luxembourg Emla 25mg/25mg crème

Malta EMLA 5% w/w Cream

Norway Emla

Poland EMLA

Portugal Emla

Spain EMLA 25 mg/g + 25 mg/g crema

Sweden EMLA

The Netherlands Emla

United Kingdom Emla Cream 5%